Juno Therapeutics (JUNO) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results
February 29, 2016 4:05 PM ESTOn track for approval of JCAR015 as soon as 2017 in relapsed/refractory adult ALL
First clinical milestone met for CD22 CAR T cell product candidate
Multiple trials enrolling using CAR/TCR product candidates to treat solid organ tumors
Celgene collaboration off to a strong start
Strong 2015 year end cash position of $1.22 billion
2016 cash burn guidance of $220 million to $250 million, with $170 million to $195 million in operating burn
Conference call to be held today at 5:00 p.m. Eastern Time
... More
